Sun–Organon: The scope, risks, and future of India's biggest pharma deal
India's largest drugmaker, Sun Pharma, has announced the acquisition of US-based Organon in a landmark $11.75 billion all-cash deal, the biggest overseas purchase by an Indian company since Tata-Corus in 2007. The move effectively doubles Sun Pharma's size, vaulting it into the top 25 global pharmaceutical companies…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
Similar episodes from other shows
More like The Morning Brief →
How can India’s pharma companies survive under Trump’s uncertainty?
Why Sun Pharma Is Betting on New Drugs
Was Mankind Pharma's IPO a good idea?
Overhauling drugs law, Maha's new bike taxi rules, and Tata Sons' chairman
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.